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Abstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a 
potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of 
lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of 
combination regimens for lung cancer, particularly for small cell lung cancer, conducted in 
Japan and overseas have been promising. Amrubicin should be included among new treatment 
strategies especially for chemoresistant patients. Here, preclinical, pharmacological, and clinical 
data on the use of amrubicin for the treatment of small cell lung cancer are reviewed.
Keywords: amrubicin, anthracycline, small-cell lung cancer, extensive disease
Introduction
Small-cell lung cancer (SCLC) accounts for 10% to 15% of all primary lung cancer and 
is a rapidly growing tumor that is highly responsive to chemotherapy and radiotherapy 
(Sher et al 2008). Nonetheless, after apparently successful induction therapy, most 
patients experience disease relapse and die within 2 years. Despite the introduction 
of new chemotherapeutic agents, including irinotecan, topotecan, paclitaxel, and 
gemcitabine, for the treatment of SCLC in the 1990s, few advances in the prolongation 
of survival in patients with this disease have been made. To control SCLC more 
effectively, new drugs are needed that are effective in patients who have not responded 
to standard treatment and who may have multidrug-resistant tumors. One such new 
effective agent may be amrubicin; the use of this drug has extensively been examined 
and approved for the treatment of both SCLC and non-SCLC in Japan.
Amrubicin
Structure and characteristics
The anthracyclines tested clinically so far have been limited to those produced by 
fermentation or semisynthetic processes. In contrast, 9-aminoanthracycline, known 
as amrubicin, is a fully synthetic drug. Amrubicin differs from daunosamine in that 
it contains a 9-amino group and a simple sugar moiety (Figure 1) (Ishizumi et al 
1987). Amrubicin is converted to its active 13-hydroxy metabolite, amrubicinol, in 
liver, kidney, and tumor tissues through the reduction of its C-13 ketone group to 
a hydroxy group by the action of cytoplasmic carbonyl reductase. Other enzymes 
metabolizing amrubicin and amrubicinol are NADPH-dependent P450 reductase and 
NAD[P]H-dependent quinone oxidoreductase. Despite the similarity of its chemical 
structure to that of a representative anthracycline, doxorubicin, amrubicin’s mode of 
action differs from that of doxorubicin. Amrubicin and amrubicinol are inhibitors of 
DNA topoisomerase II, exerting their cytotoxic effects by stabilizing a topoisomerase 
II-mediated cleavable complex, and are approximately only one-tenth as potent as 
doxorubicin in producing DNA intercalation (Hanada et al 1998).Drug Design, Development and Therapy 2008:2 190
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Preclinical studies
In in vitro experiments, amrubicin and its metabolite 
amrubicinol have been found to be active against a broad 
spectrum of human cell lines established from cancers of the 
lung, prostate, urinary bladder, colon, kidney, pancreas, and 
uterus (Yamaoka et al 1998). Amrubicinol has been shown 
to exhibit a 20- to 220-fold more potent antitumor activity in 
vitro than amrubicin itself, with amrubicinol being as potent 
as doxorubicin. In addition, amrubicin and amrubicinol 
have also been demonstrated to show some degree of 
non-cross resistance with doxorubicin. However, like other 
anthracyclines, the cytotoxicity and intracellular accumulation 
of amrubicin in P-glycoprotein overexpressed MDR1 
gene-transfected LLC-PK1 (L-MDR1) cells were signiﬁ  cantly 
decreased compared with those in parental LLC-PK1 cells, 
suggesting that the antitumor efﬁ  cacy of amrubicin is affected 
by the expression level of P-glycoprotein in lung cancer cells 
in chemotherapy (Takara et al 2002; Hira et al 2008).
Amrubicin has been shown to be more effective against 
5 human xenografts (1 breast cancer, 1 lung cancer, 
and 3 gastric cancers), equally effective against 2 gastric 
cancers, and less effective against a lung cancer and 2 gastric 
cancer tumors, compared with doxorubicin (Morisada et al 
1989; Noguchi et al 1998).
Amrubicin caused dose-dependent weight loss, ataxia, 
myelosuppression, and hair loss in mice after a single 
intravenous injection. The maximum tolerated dose (MTD) 
for such administration was estimated to be 25 mg/kg in 
4 mouse strains.
Cardiotoxicity is one of the dose-limiting toxicities 
of anthracyclines. However, amrubicin showed little 
delayed-type cardiotoxicity in rabbit and dog experimental 
models (Suzuki et al 1997; Noda et al 1998). Furthermore, 
amrubicin did not aggravate doxorubicin-induced myocardial 
injury.
Clinical studies
Amrubicin monotherapy
Phase II study in previously untreated patients 
with extensive-stage SCLC
Thirty-five previously untreated patients with 
extensive-disease SCLC (ED-SCLC) were enrolled in 
the study (Yana et al 2007). Amrubicin was adminis-
tered as a daily intravenous injection of 45 mg/m2/day 
for 3 consecutive days every 3 weeks. Of the 33 eligible 
patients, 3 showed a complete response (CR) and 22 showed 
a partial response (PR), with an overall response rate of 
75.8% (95% conﬁ  dence intervals [CI], 57.7%–88.9%). 
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Figure 1 Structure of amrubicin and its active metabolite, amrubicinol.Drug Design, Development and Therapy 2008:2 191
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The MST and 1-year survival periods were 11.7 months 
and 48.5%, respectively. The most common toxicity was 
hematologic toxicity.
Phase II trial for the treatment of refractory 
or relapsed SCLC
SCLC patients with measurable disease who had been 
previously treated with at least one platinum-based 
chemotherapeutic regimen were entered into the trial 
(Onoda et al 2006). Since these patients had previously 
received chemotherapy or radiotherapy, the amrubicin was 
administered at a reduced dose of 40 mg/m2 per day × 3 days 
every 3 weeks. Sixty patients (16 refractory and 44 sensitive) 
were enrolled. The overall response rates were 50% (95% 
CI, 25%–75%) in the refractory group and 52% (95% CI, 
37%–68%) in the sensitive group. The overall survival 
and 1-year survival periods in the refractory-disease group 
were 10.3 months and 40%, respectively, and in the sensi-
tive-disease group 11.6 months and 46%, respectively. 
The grade 3 or 4 hematologic toxicities were neutropenia 
(83%), thrombocytopenia (20%), and anemia (33%). 
Febrile neutropenia was observed in 3 patients (5%). The 
non-hematologic toxicities were mild. Thus, amrubicin 
showed signiﬁ  cant activity against SCLC, with predictable 
and manageable toxicities.
Randomized phase II trial for second-line treatment 
of sensitive SCLC
A randomized phase II trial of amrubicin versus topotecan 
was conducted in patients with ED-SCLC sensitive to 
platinum-based ﬁ  rst-line chemotherapy (recurrence or pro-
gression 90 days after ﬁ  rst-line chemotherapy (Jotte et al 
2008). Patients were randomized at a 2:1 ratio to receive either 
amrubicin or topotecan. The interim data from 76 patients 
were as follows: amrubicin improved the overall response 
rate compared with topotecan (34% versus 3.8%; p  0.004). 
A trend toward a longer progression-free survival time in the 
amrubicin group (4.6 months) compared with the topotecan 
group (3.5 months) was seen. They concluded that amrubicin 
is active in non-Japanese patients and is well tolerated, with 
myelosuppression being the main dose-limiting toxicity.
Phase II trial for second-line treatment 
of refractory SCLC
Patients with SCLC who progress while receiving ﬁ  rst-line 
chemotherapy or who relapse within 3 months are much less 
likely to respond to additional chemotherapy and have an 
expected MST of 6 months or less. Single-agent topotecan 
in this population results in a response rate of 2% to 7%. 
Seventy-ﬁ  ve patients were enrolled in a trial (Ettinger et al 
2008). Of the 69 patients who were treated, 11 patients attained 
a PR and one patient had a CR, with an overall response rate 
of 17.4%, which compares favorably with the historically 
observed rate for topotecan. Thus, amrubicin is a promising 
new anthracycline warranting further study. A phase III trial 
in second-line SCLC patients is now underway, as well as a 
phase II study in ﬁ  rst-line SCLC patients.
Combination chemotherapy involving amrubicin
Phase I-II study of amrubicin and cisplatin for previously 
untreated patients with extensive-stage SCLC
Patients with histologically or cytologically proven 
measurable ED-SCLC, no previous chemotherapy, and good 
prognostic factors were enrolled in this trial (Ohe et al 2005). 
Amrubicin was administered on days 1 to 3 and cisplatin 
was administered on day 1, every 3 weeks. Four patients 
were enrolled at dose level 1 (amrubicin, 40 mg/m2/day and 
cisplatin, 60 mg/m2) and 3 patients were enrolled at dose 
level 2 (amrubicin, 45 mg/m2/day and cisplatin 60, mg/m2). 
The maximum-tolerated dose and the recommended dose 
(RD) were found to be level 2 and level 1, respectively. The 
response rate at the RD was 87.8% (36/41). The median 
survival and the 1-year survival rate were encouraging, 
13.6 months and 56.1%, respectively.
Discussion
Because of the systemic nature of SCLC, chemotherapy 
offers the best hope of improving treatment outcomes. 
However, over the past 3 decades, therapeutic advances for 
this disease have occurred very slowly.
Amrubicin markedly inhibits topoisomerase II activity 
and has exhibited a broad spectrum of antitumor activity 
in preclinical studies (Yamaoka et al 1998). The results 
of clinical studies examining amrubicin as a single agent 
or as a component of combination regimens for SCLC 
have been promising, with manageable, non-cumulative 
toxicities (Ohe et al 2005; Onoda et al 2006; Yana et al 
2007). At present, two randomized trials to determine the 
exact role of amrubicin in the treatment of SCLC are now 
underway in Japan: one examining cisplatin + amrubi-
cin versus cisplatin + irinotecan in previously untreated 
patients with ED-SCLC, and one examining amrubicin 
versus carboplatin + etoposide in elderly patients with 
ED-SCLC. Two clinical trials have conﬁ  rmed the effective-
ness of amrubicin in US patients with SCLC. One of these 
trials was a randomized phase II trial comparing amrubicin 
with topotecan as a second-line treatment in a treatment Drug Design, Development and Therapy 2008:2 192
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sensitive-group (Ettinger et al 2008). The other was a 
phase II trial in patients refractory to ﬁ  rst-line chemotherapy 
(Ettinger et al 2008). Amrubicin may be a promising new 
addition to treatment strategies for SCLC, especially for 
chemoresistant patients. However, there are only a few 
clinical trials of this agent and the number of the patients 
treated with this drug is still quite small. Therefore, further 
studies exploring the role of amrubicin as a single agent 
or in combination with cytotoxic agents as well as novel 
molecular-targeted drugs for the treatment of other various 
malignancies are warranted. Lastly, since most of the trials 
with amrubicin have been done in Japan, future clinical 
studies to deﬁ  ne the beneﬁ  ts and risk associated with amru-
bicin as a single agent or in combination for cancer therapy 
conducted overseas are eagerly awaited.
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